TRAIL induces apoptosis in cancer cells, and OPG (osteoprotegerin) can act as a decoy receptor for TRAIL, potentially inhibiting its pro-apoptotic effects and thus contributing to cell survival in breast cancer [20,26]. Here, TNFRSF11B is linked to breast carcinoma.